Revolution Medicines, Inc.
RVMDHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeRevolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company carries a $40.08B market cap, placing it firmly in the large-cap category. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers.
Market Cap
$40.08B
Beta
1.40
P/E (TTM)
—
P/E (Fwd)
-32.10
EPS (TTM)
$-8.87
EPS (Fwd)
$-5.83
ROE
-79.1%
ROA
-30.1%
Cash
$3.94B
Total Debt
$1.19B
Free CF
-$711.6M
52W Change
222.4%
Annual Financials
Cash vs Debt
Where RVMD stands vs its 150-day and 200-day moving averages
As of the October 13, 2026 close, RVMD finished 16.94% above its 150-day moving average ($165.85) and 29.75% above its 200-day moving average ($149.48). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is RVMD overbought or oversold?
At the October 13, 2026 close, RVMD's RSI(14) was 51.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $3.94B in cash comfortably exceeding the $1.19B debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$711.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -79.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $29.4M (2021) to $0 (2025), a 100% decline worth watching.
With cash comfortably exceeding debt, RVMD has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Revolution Medicines, Inc.'s trajectory.